Perspective Therapeutics (NYSEAMERICAN:CATX) Earns “Outperform” Rating from Wedbush

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “outperform” rating restated by Wedbush in a note issued to investors on Monday,RTT News reports. They presently have a $11.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 253.70% from the stock’s previous close.

A number of other research analysts have also commented on the company. B. Riley reaffirmed a “buy” rating and issued a $12.00 price objective (up from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a report on Saturday, July 12th. BTIG Research initiated coverage on Perspective Therapeutics in a report on Friday, October 10th. They issued a “buy” rating and a $14.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a report on Friday, October 3rd. Four research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.70.

Perspective Therapeutics Stock Down 2.5%

Shares of NYSEAMERICAN CATX opened at $3.11 on Monday. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average price is $3.60 and its two-hundred day moving average price is $3.25. Perspective Therapeutics has a one year low of $1.60 and a one year high of $12.90.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently modified their holdings of the stock. Ground Swell Capital LLC bought a new stake in shares of Perspective Therapeutics during the 2nd quarter valued at $56,000. Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics in the 2nd quarter valued at $61,000. MetLife Investment Management LLC increased its stake in shares of Perspective Therapeutics by 40.9% in the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after purchasing an additional 9,082 shares during the last quarter. Trueblood Wealth Management LLC lifted its position in shares of Perspective Therapeutics by 210.6% during the 2nd quarter. Trueblood Wealth Management LLC now owns 69,061 shares of the company’s stock worth $238,000 after buying an additional 46,825 shares during the last quarter. Finally, Taylor & Morgan Wealth Management LLC lifted its position in shares of Perspective Therapeutics by 4.4% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock worth $323,000 after buying an additional 4,000 shares during the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.